The clinical failure of nerve growth factor (NGF) inhibitors for arthritis pain may finally have an explanation that reshapes how researchers view this promising but problematic therapeutic target. Despite showing excellent pain relief in trials, NGF antibodies were shelved after unexplained joint deterioration in some patients, leaving a critical knowledge gap about this protein's direct effects on joint tissues.
Investigators injected healthy mouse knee joints with NGF twice weekly for four weeks and documented a cascade of joint pathology. The 500-nanogram dose triggered knee swelling, heightened pain sensitivity, synovial inflammation, increased bone mineral density in subchondral regions, and early bone spur formation. Remarkably, cartilage remained intact throughout this process, suggesting NGF drives osteoarthritis-like changes through non-cartilage mechanisms. Single-cell RNA sequencing revealed upregulated genes controlling nerve sprouting, tissue fibrosis, and bone formation, while sensory neurons showed enhanced growth pathway activation.
This mechanistic insight challenges the traditional view of NGF as merely a pain mediator. The findings suggest NGF actively orchestrates joint remodeling through coordinated effects on bone, synovium, and neural networks—potentially explaining why blocking it therapeutically led to unexpected joint complications. For the millions suffering from osteoarthritis, this work illuminates why targeting NGF proved more complex than anticipated and may guide safer approaches to manipulating this pathway. The research also raises questions about whether elevated NGF in arthritic joints contributes to disease progression beyond just pain signaling.